催产素治疗单纯性肥胖的疗效与安全性研究

Efficacy and safety of oxytocin for treatment of simple obesity

摘要:

目的 探讨催产素（OXT）鼻内给药治疗单纯性肥胖患者的疗效与安全性。方法 采用随机、双盲、 安慰剂对照的方法将符合研究要求的30 例单纯性肥胖患者分为治疗组和安慰剂组，分别接受催产素鼻喷剂和安 慰剂（生理盐水）鼻喷剂，治疗12 周。观察两组治疗前后的体重、体重指数（BMI）、腰围、臀围、血脂及肝 肾功能变化情况，评价其临床疗效和安全性。用酶联免疫法（ELISA）检测两组治疗前0 周和治疗后12 周血 清C 反应蛋白（CRP）和脂联素（APN）水平。结果 治疗后12 周，治疗组体重、BMI、腰围、臀围下降幅度与 安慰剂组比较，差异有统计学意义（P <0.05），治疗组大于安慰剂组。治疗组治疗后12 周TC、TG、LDL-C 与 治疗前比较，差异有统计学意义（P <0.05），均有所下降，而HDL-C 在治疗前后差异无统计学意义（P >0.05）。 治疗后12 周，治疗组TC、TG、LDL-C 与安慰剂组比较，差异有统计学意义（P <0.05），治疗组低于安慰剂 组。治疗后12 周，治疗组ALT 与治疗前比较，差异有统计学意义（P <0.05），治疗后12 周较治疗前下降。治疗 组AST、Scr、BUN 治疗前后差异无统计学意义（P >0.05）。与治疗前比较，治疗后12 周治疗组CRP 下降， APN 升高（P <0.05）。与安慰剂组比较，治疗后12 周治疗组CRP 下降，APN 升高（P <0.05）。结论 催产素 可以减轻单纯性肥胖患者体重，还能改善血脂紊乱，改善肥胖慢性炎症状态，未发现有肝肾功能的损害。

关键词:催产素;单纯性肥胖;脂联素;C 反应蛋白

Abstract:

Objective To evaluate the efficacy and safety of oxytocin nasal spray in treating simple obesity. Methods Thirty cases of simple obesity were divided into two groups by a randomized, double-blind, placebocontrolled trial. The treatment group had 15 cases treated with oxytocin nasal spray, the placebo-control group had 15 cases treated with placebo (saline) nasal spray for a continuous 12-week period. The changes of body weight, body mass index (BMI), waist circumference, hip circumference, blood lipids, and liver and kidney functions were observed before and after treatment. Enzyme-linked immunosorbent assay (ELISA) was used to detect serum adiponectin and CRP levels. Results Compared with the placebo-control group, the reduction ranges of body weight, BMI, waist circumference and hip circumference at the end of the 12th week increased significantly in the treatment group (P < 0.05). In the treatment group, TC, LDL-C and TG decreased significantly at the end of the 12th week compared to those before treatment (P < 0.05), but HDL-C had no significant change at the end of the 12th week. At the end of the 12th week, TC, LDL-C and TG in the treatment group were lower those in the placebo-control group (P < 0.05). ALT reduced significantly in the treatment group at the end of the 12th week compared with that before treatment (P < 0.05). There was no significant difference in AST, Scr or BUN before and after treatment (P > 0.05). CRP decreased while adiponectin increased significantly in the treatment group at the end of the 12th week compared with those before treatment (P < 0.05). Compared with the placebo-control group, CRP decreased significantly and adiponectin increased significantly in treatment group at the end of the 12th week (P < 0.05). Conclusions Oxytocin can reduce the body weight of obese patients, improve lipid metabolism and ameliorate obesity chronic inflammatory state. Oxytocin has no adverse effect on hepatic or renal functions.

Key words:oxytocin; obesity; adiponectin; CRP